Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease

Haematologica

Volumn 92, Issue 6, 2007, Pages 857-858

  Kawabata, Hiroshi ^a   Tomosugi, Naohisa ^b   Kanda, Junya ^a   Tanaka, Yasuhiro ^a   Yoshizaki, Kazuyuki ^c   Uchiyama, Takashi ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Castleman's disease; Hepcidin; Interleukin 6; Iron metabolism; Tocilizumab

Indexed keywords

ATLIZUMAB; C REACTIVE PROTEIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; FERRITIN; HEMOGLOBIN; HEPCIDIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; IRON; PREDNISOLONE; ANTIMICROBIAL CATIONIC PEPTIDE; MONOCLONAL ANTIBODY;

ADULT; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; CASE REPORT; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; MEAN CORPUSCULAR VOLUME; MICROCYTIC ANEMIA; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; BLOOD; DRUG ANTAGONISM; IMMUNOLOGY; LETTER;

ADULT; ANTIBODIES, MONOCLONAL; ANTIMICROBIAL CATIONIC PEPTIDES; DOWN-REGULATION; FEMALE; GIANT LYMPH NODE HYPERPLASIA; HUMANS; RECEPTORS, INTERLEUKIN-6;

EID: 34347219438     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10794     Document Type: Article

References (10)

1. Hirano T, Kishimoto T. Interleukin 6 and plasma cell neoplasias. Prog Growth Factor Res 1989;1:133-42.
2. Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 1989;74:1360-7.
3. Waterston A, Bower M. Fifty years of multicentric Castleman's disease. Acta Oncol 2004;43:698-704.
4. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005;106:2627-32.
5. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003;101:2461-3.
6. Kemna E, Pickkers P, Nemeth E, van der Hoeven H, Swinkels D. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood 2005;106:1864-6.
7. Lee P, Peng H, Gelbart T, Wang L, Beutler E. Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc Natl Acad Sci USA 2005;102:1906-10.
8. Ganz T. Hepcidin - a regulator of intestinal iron absorption and iron recycling by macrophages. Best Pract Res Clin Haematol 2005;18:171-82.
9. Tomosugi N, Kawabata H, Wakatabe R, Higuchi M, Yamaya H, Umehara H, et al. Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System(R). Blood 2006;108:1381-7.
10. Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004;126:989-96.